

We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
![]() | Petros Pharmaceuticals Inc | 0.1369 | 0.0791 | 136.85% | 1,587,439,806 |
![]() | OSR Holdings Inc | 3.69 | 2.09 | 130.63% | 96,032,603 |
![]() | VivoPower International PLC | 4.2307 | 1.97 | 87.20% | 142,991,253 |
![]() | Lixiang Education Holding Company Ltd | 18.42 | 8.02 | 77.12% | 432,120 |
![]() | SurgePays Inc | 2.341 | 0.961 | 69.64% | 69,701,331 |
![]() | AquaBounty Technologies Inc | 1.01 | 0.3333 | 49.25% | 44,357,393 |
![]() | Ocean Biomedical Inc | 0.0837 | 0.0269 | 47.36% | 876,640,823 |
![]() | Edible Garden AG Inc | 3.835 | 0.945 | 32.70% | 530,898 |
![]() | Digital Ally Inc | 0.0469 | 0.0109 | 30.28% | 190,942,344 |
![]() | Hour Loop Inc | 2.0499 | 0.4699 | 29.74% | 3,072,403 |
![]() | Ridgetech Inc | 1.2124 | 0.2733 | 29.10% | 1,293,071 |
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland, March 26, 2025 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.
Completed AT&T integration positions company for its most aggressive growth phase to date with projected positive cash flow from operations in 2025 BARTLETT, Tenn., March 25, 2025 /PRNewswire/ -- SurgePays, Inc. (Nasdaq: SURG) ("SurgePays" or the "Company"), a wireless and point of sale technology company, today announced its financial results for the year ended December 31, 2024, and is issuing guidance of over $200 million in revenue over the next 12 months and positive cash flow from operations before the end of 2025, following the successful integration and official launch with AT&T.
BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant, for gross proceeds of approximately $10 million, before deducting placement agent fees and offering expenses payable by the Company.
Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
LWLG | Lightwave Logic Inc | ||
ELTP | Elite Pharmaceuticals Inc | ||
HMBL | HUMBL Inc | ||
4 | TGLO | TheGlobe.com Inc | |
5 | NB | Niocorp Developments Ltd | |
6 | TPTW | TPT Global Tech Inc |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
![]() | Bitcoin | 86,888.20 | 0.00 | 0.00% | 1.72T | 3,694,200,091 |
![]() | Ethereum | 2,009.13 | 0.00 | 0.00% | 242.19B | 1,523,802,778 |
![]() | Tether USD | 1.00 | 0.00 | 0.00% | 141.93B | 326,056,835 |
![]() | Ripple | 2.35 | 0.00 | 0.00% | 135.74B | 660,419,995 |
![]() | Binance Coin | 617.17 | -0.695106 | -0.11% | 97.54B | 160,128,241 |
![]() | Solana | 137.05 | -0.320 | -0.23% | 67.06B | 862,700,959 |
![]() | USD Coin | 0.9999 | 0.00 | 0.00% | 56.1B | 1,013,743,387 |
![]() | Dogecoin | 0.19475 | -0.00012 | -0.06% | 28.85B | 687,536,155 |
![]() | Cardano | 0.7289 | 0.00 | 0.00% | 26.18B | 238,959,570 |
![]() | TRON | 0.232001 | 0.00121 | 0.52% | 19.87B | 106,307,157 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions